Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 20/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6820800 | 1.00 | NPY5R (0.65) | NPY5R | |
| SCHEMBL13950030 | 0.90 | NPY5R (0.65) | NPY5R | |
| SCHEMBL13403193 | 0.90 | NPY5R (0.65) | NPY5R | |
| SCHEMBL1582177 | 0.90 | NPY5R (0.65) | NPY5R | |
| SCHEMBL1582179 | 0.90 | NPY5R (0.65) | NPY5R | |
| SCHEMBL6820751 | 0.85 | NPY5R (0.56) | NPY5R | |
| SCHEMBL6820752 | 0.85 | NPY5R (0.56) | NPY5R | |
| SCHEMBL17804385 | 0.82 | NPY5R (0.54) | NPY5R | |
| SCHEMBL13710674 | 0.82 | NPY5R (0.54) | NPY5R | |
| SCHEMBL1582282 | 0.82 | NPY5R (0.60) | NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063987-A1 | Method for producing alkoxymalononitriles | BARTEK JOHANNES (CH) | 2004-04-01 | — | — | US | claimed |
| US-6673957-B2 | DEHYDRATION OF ALKOXY MALONIC ACID DIAMIDES | LONZA AG (CH) | 2004-01-06 | — | — | US | claimed |
| US-20030144538-A1 | Method for producing alkoxy malonic acid dinitriles | LONZA AG (CH) | 2003-07-31 | — | — | US | claimed |
| US-20120149703-A1 | AZA-SUBSTITUTED SPIRO DERIVATIVES | JITSUOKA MAKOTO (JP) | 2012-06-14 | — | — | US | disclosed |
| US-8158791-B2 | Aza-substituted spiro derivatives | MSD K.K. (JP) | 2012-04-17 | — | — | US | disclosed |
| EP-1953165-B1 | AZA-SUBSTITUTED SPIRO DERIVATIVE | MSD KK (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-20090258871-A1 | Aza-Substituted Spiro Derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-10-15 | — | — | US | disclosed |
| EP-1953165-A1 | AZA-SUBSTITUTED SPIRO DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-6723847-B2 | 3-OXO-N-(5-PHENYL-2-PYRIMIDINYL)SPIRO(4-AZAISOBENZOFURAN-1 (3H),1'-CYCLOHEXANE)-4'-CARBOXAMIDE; NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-04-20 | — | — | US | disclosed |
| US-20040063987-A1 | Method for producing alkoxymalononitriles | BARTEK JOHANNES (CH) | 2004-04-01 | — | — | US | disclosed |
| US-20040063987-A1 | Method for producing alkoxymalononitriles | BARTEK JOHANNES (CH) | 2004-04-01 | — | — | US | disclosed |
| US-6673957-B2 | DEHYDRATION OF ALKOXY MALONIC ACID DIAMIDES | LONZA AG (CH) | 2004-01-06 | — | — | US | disclosed |
| US-20030220499-A1 | Novel spiro compounds | MSD K.K. (JP) | 2003-11-27 | — | — | US | disclosed |
| US-20030144538-A1 | Method for producing alkoxy malonic acid dinitriles | LONZA AG (CH) | 2003-07-31 | — | — | US | disclosed |
| US-20020165391-A1 | Neuropeptide Y receptor antagonists | MSD K.K. (JP) | 2002-11-07 | — | — | US | disclosed |
| US-6462053-B1 | NEUROPEPTIDE Y RECEPTOR ANTAGONISTS; CARDIOVASCULAR AND CENTRAL NERVOUS SYSTEM DISORDERS AND METABOLIC DISEASES; HYPERTENSION, NEPHROPATHY, HEART DISEASE, VASOSPASM, ARTERIOSCLEROSIS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-10-08 | — | — | US | disclosed |
| US-6388077-B1 | CARDIOVASCULAR DISORDERS; CENTRAL NERVOUS SYSTEM DISORDERS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-14 | — | — | US | disclosed |
| US-6335345-B1 | NEUROPEPTIDE Y RECEPTOR ANTAGONISTS; OBESITY AND BULIMIA TREATMENT; CENTRAL NERVOUS SYSTEM, PSYCHOLOGICAL, METABOLIC AND EATING DISORDERS; ANTIDIABETIC AGENTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149703-A1 | AZA-SUBSTITUTED SPIRO DERIVATIVES | AZI2, NR3C2, DNMT3A | NPY5R 423/4885 |
| US-20040063987-A1 | Method for producing alkoxymalononitriles | AQP1, KCNH1, CNOT1 | NPY5R 3360/4885 |
| US-20030144538-A1 | Method for producing alkoxy malonic acid dinitriles | ME1, ADH1C, CA6 | NPY5R 4429/4885 |
| US-20030220499-A1 | Novel spiro compounds | NPY1R, OPRK1, OPRM1 | NPY5R 43/4885 |
| US-20020165391-A1 | Neuropeptide Y receptor antagonists | NPY1R, NPY2R, NPY4R | NPY5R 4/4885 |
| US-20090258871-A1 | Aza-Substituted Spiro Derivatives | AZI2, NR3C2, DNMT3A | NPY5R 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.